• 1. Fatty acid positional distribution in colostrum and mature milk of women living in Inner Mongolia, North Jiangsu and Guangxi of China?
  Long Deng,Qian Zou,Biao Liu,Wenhui Ye,Chengfei Zhuo,Li Chen,Ze-Yuan Deng,Ya-Wei Fan,Jing Li Food Funct., 2018,9, 4234-4245
• 2. Evidence for the intrinsic nature of band-gap states electrochemically observed on atomically flat TiO2(110) surfaces?
  Shintaro Takata,Yoshihiro Miura Phys. Chem. Chem. Phys., 2014,16, 24784-24789
• 3. Evidence of pre-micellar aggregates in aqueous solution of amphiphilic PDMS–PEO block copolymer?
  Domenico Lombardo,Gianmarco Munaò,Pietro Calandra,Luigi Pasqua,Maria Teresa Caccamo Phys. Chem. Chem. Phys., 2019,21, 11983-11991
• 4. Establishing the accuracy of position-specific carbon isotope analysis of propane by GC-pyrolysis-GC-IRMS
  ChangjieLiu,PengLiu,XiaofengWang,XiaoqiangLi,JuskeHorita
• 5. Dissociation of aryl sulfonyl phthalimide radical anions: relevance to the biological activity of arylsulfonyl amides?
  Abdelaziz Houmam,Emad M. Hamed Chem. Commun., 2012,48, 11328-11330

Recent Advances in the Application of 3-Methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)aniline (CAS: 1312535-18-4) in Chemical Biology and Pharmaceutical Research

The compound 3-Methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)aniline (CAS: 1312535-18-4) has recently garnered significant attention in the field of chemical biology and pharmaceutical research due to its versatile applications in drug discovery and development. This boronic acid derivative serves as a crucial intermediate in the synthesis of various bioactive molecules, particularly in the construction of boron-containing compounds that exhibit unique pharmacological properties. Recent studies have highlighted its role in Suzuki-Miyaura cross-coupling reactions, a cornerstone methodology in modern medicinal chemistry for the construction of complex molecular architectures.

One of the most notable applications of this compound is in the development of proteasome inhibitors, a class of therapeutic agents with demonstrated efficacy in treating multiple myeloma and other malignancies. Researchers have utilized 3-Methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)aniline as a key building block in the synthesis of novel boronic acid-based proteasome inhibitors, which exhibit enhanced selectivity and potency compared to their predecessors. The boronate moiety in this compound plays a pivotal role in forming reversible covalent bonds with the active site threonine residues of the proteasome, thereby inhibiting its function.

In addition to its applications in cancer therapy, recent studies have explored the potential of this compound in the development of antimicrobial agents. The unique electronic properties imparted by the boronic acid group enable interactions with bacterial enzymes and cell wall components, offering new avenues for combating antibiotic-resistant pathogens. Several research groups have reported promising results in using derivatives of 3-Methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)aniline as inhibitors of β-lactamases, enzymes responsible for resistance to β-lactam antibiotics.

The compound's utility extends to the field of chemical biology, where it has been employed as a molecular probe for studying protein-ligand interactions. Its fluorescent properties, when appropriately functionalized, allow for real-time monitoring of biological processes, making it a valuable tool in high-throughput screening and target validation studies. Recent advancements in bioconjugation techniques have further expanded its applications in the development of targeted therapeutics and diagnostic agents.

From a synthetic chemistry perspective, researchers have made significant progress in optimizing the preparation of 3-Methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)aniline, developing more efficient and environmentally friendly protocols. Recent publications describe improved catalytic systems and milder reaction conditions that enhance yield and purity while reducing the generation of hazardous byproducts. These advancements are particularly important given the growing demand for this compound in both academic and industrial settings.

Looking forward, the unique properties of 3-Methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)aniline position it as a promising candidate for addressing several unmet medical needs. Ongoing research is exploring its potential in neurodegenerative diseases, where boron-containing compounds have shown neuroprotective effects, as well as in the development of next-generation antiviral agents. As our understanding of boron biology continues to evolve, this compound is likely to play an increasingly important role in bridging the gap between chemical synthesis and biological activity.

• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)